Predictions
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€239.50
07.02.21
07.02.21
-
07.02.22
07.02.22
-38.71%
19.11.21
19.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
High dividend yield expected
Innovative
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€199.00
25.01.21
25.01.21
€250.00
25.01.22
25.01.22
-46.48%
17.01.22
17.01.22
Fair valuation
Known brand
Growths faster than the competition
Revenue growth >5% per year expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€191.40
21.01.21
21.01.21
€200.00
4.49%
26.01.21
26.01.21
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
BayWa AG NA
Start price
Target price
Perf. (%)
€36.00
11.01.21
11.01.21
€39.00
11.01.22
11.01.22
31.11%
12.01.22
12.01.22
Could be worthwhile Investment >10% per year
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€152.40
06.01.21
06.01.21
€200.00
16.80%
30.03.21
30.03.21
Medium risks for its business
Schaeffler AG
Start price
Target price
Perf. (%)
€5.55
04.11.20
04.11.20
€7.90
04.11.21
04.11.21
25.95%
05.11.21
05.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Schaeffler AG
Start price
Target price
Perf. (%)
€5.10
28.10.20
28.10.20
€4.50
04.11.21
04.11.21
8.82%
04.11.20
04.11.20
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€162.60
16.10.20
16.10.20
€175.00
04.11.21
04.11.21
8.86%
20.01.21
20.01.21
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Schaeffler AG
Start price
Target price
Perf. (%)
€5.77
09.10.20
09.10.20
€6.50
28.10.20
28.10.20
-11.54%
28.10.20
28.10.20
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Südzucker AG
Start price
Target price
Perf. (%)
€17.09
16.09.20
16.09.20
€40.00
04.11.21
04.11.21
-18.67%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€135.80
08.09.20
08.09.20
€175.00
16.10.20
16.10.20
20.03%
16.10.20
16.10.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€126.00
06.09.20
06.09.20
€155.00
04.11.21
04.11.21
28.41%
05.11.20
05.11.20
Medium risks for its business
CompuGroup Medical SE & Co. KGaA
Start price
Target price
Perf. (%)
€80.35
02.09.20
02.09.20
€90.00
04.11.21
04.11.21
-6.85%
08.12.20
08.12.20
EBIT growth >5% per year expected
ROE higher than 15% per year
positive Cash Flow expected
Could be worthwhile Investment >10% per year
Schaeffler AG
Start price
Target price
Perf. (%)
€5.54
22.08.20
22.08.20
€5.00
09.10.20
09.10.20
4.16%
09.10.20
09.10.20
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€155.40
20.08.20
20.08.20
-
05.09.20
05.09.20
-18.92%
05.09.20
05.09.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Schaeffler AG
Start price
Target price
Perf. (%)
€6.47
19.08.20
19.08.20
€6.90
04.11.21
04.11.21
2.16%
02.02.21
02.02.21
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Innovative
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€150.60
18.08.20
18.08.20
€210.00
04.11.21
04.11.21
29.61%
22.01.21
22.01.21
Fair valuation
Known brand
Growths faster than the competition
Revenue growth >5% per year expected